Adaptimmune and Alpine Immune Sciences Partner for Development of NextGeneration SPEAR TCell Products Using Alpines SIP and TIP Technology

Adaptimmune and Alpine Immune Sciences Partner for Development of Next-Generation SPEAR T-Cell Products Using Alpine’s SIP and TIP Technology

10:50 EDT 15 May 2019 | Speciality Pharma Journal

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced a collaboration and license agreement to develop next-generation SPEAR …

More From BioPortfolio on "Adaptimmune and Alpine Immune Sciences Partner for Development of Next-Generation SPEAR T-Cell Products Using Alpine’s SIP and TIP Technology"